World’s oldest blood pressure drug may help treat aggressive brain tumour, study finds

Researchers at the University of Pennsylvania report in Science Advances that hydralazine, a 70‑year‑old antihypertensive widely used in pregnancy, directly binds and inhibits the oxygen‑sensing enzyme ADO (2‑aminoethanethiol dioxygenase), a molecular switch that helps cells survive hypoxia; this mechanism explains hydralazine’s newly observed ability to halt growth of aggressive brain tumours in preclinical work and reveals an unexpected biological link between hypertensive disorders and brain cancer. The finding both creates a rationale for repurposing or optimizing hydralazine‑derived compounds as oncology agents and suggests routes to develop safer, more selective treatments for pregnancy‑related hypertension, with potential implications for drug development and IP strategies in cardiovascular and cancer therapeutics.

Analysis

Researchers at the University of Pennsylvania report in Science Advances that hydralazine, a more-than-70-year-old antihypertensive commonly used in pregnancy and described as a first-line treatment for pre-eclampsia (which contributes to 5–15% of maternal deaths worldwide), directly binds and inhibits the oxygen-sensing enzyme ADO (2-aminoethanethiol dioxygenase). The team links this molecular interaction to an ability to halt growth of aggressive brain tumours, providing a mechanistic explanation for previously observed anticancer activity and revealing an unexpected biological connection between hypertensive disorders and tumor hypoxia biology.

ADO functions as a rapid biochemical switch that senses falling oxygen and promotes cell survival in hypoxic conditions; hydralazine’s binding “silences the alarm,” undermining a survival pathway cancer cells use. This mechanistic clarity creates a rationale for repurposing hydralazine or designing optimized derivatives that target ADO more selectively for oncology indications while informing safer, targeted approaches for pregnancy-related hypertension.

Commercial and clinical translation remain the key uncertainties: the report is mechanistic and preclinical in nature, so human efficacy, safety (especially in pregnant populations), dose optimization, and IP/ licensing pathways will determine real market impact. Market sentiment reflected in the signals is mildly positive but limited (market_impact_score ~0.25), consistent with early-stage scientific yet uncertain commercial prospects.

Key Decisions for Investors

• Monitor Penn-related licensing, academic spinout activity and any IP filings tied to hydralazine/ADO inhibition as near-term value catalysts
• Track announcements of preclinical-to-clinical transition or first-in-human oncology trials targeting ADO and consider small, targeted exposure to developers that secure clear clinical milestones
• Avoid increasing core allocations based solely on this study; wait for human safety and efficacy data given the mechanistic evidence is preclinical and pregnancy-safety considerations add regulatory complexity
• Prioritize opportunities with demonstrable patent protection and programs explicitly focused on optimizing selectivity and safety of hydralazine derivatives, as these firms are more likely to capture licensing or acquisition value
• Watch for partnerships between larger pharma and academic groups or biotechs—such deals would materially de-risk commercialization but monitor regulatory signals regarding pregnancy-related indications before taking significant positions